GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management. Among incretin-based drugs, glucagon-like peptide 1 (GLP-1) receptor agonists are a promising therapeutic option for patients with diabetic kid...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ji Hee, Park, So Young, Lee, Da Young, Kim, Nan Hee, Seo, Ji A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Nephrology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995488/
https://www.ncbi.nlm.nih.gov/pubmed/35391537
http://dx.doi.org/10.23876/j.krcp.22.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995488/
https://www.ncbi.nlm.nih.gov/pubmed/35391537
http://dx.doi.org/10.23876/j.krcp.22.001

Ejemplares similares